The diseases … The cures …
New cancer drug shown to be extremely effective in Phase I trials on patients with solid tumors or brain tumors and produced no significant side effects. Developed by a Cincinnati biotech firm, the biologic-type drug is being trialed at four sites across the country; NoName is on this drug through a trial at the University of New Mexico. BXQ-350 kills over 60 different types of human cancer cells in test tubes and "is toxic to cancer cells, only. The nanovesicals bypass the blood brain barrier. BXQ-350 has an entirely new and novel mechanism of action. "
R&D biotech company website: https://www.bexionpharma.com
Bexion social media:
https://twitter.com/BexionPharma
https://www.facebook.com/Bexion
Manufacturer of active ingredient: https://www.ptcommunity.com/wire/cytovance-biologics-inc-announces-bexion-pharmaceuticals-inc-has-chosen-cytovance-manufacture
————————-
Clinical trial info:
"Bexion Pharmaceuticals, Inc. (Bexion) announces the start of a Phase 1b study of BXQ-350, an open-label study in adult patients with advanced solid tumors. The company announced in September 2017 the successful completion of the First-in-Human Phase 1a trial, where four sites (University of Cincinnati, Ohio State University, University of Kentucky and University of New Mexico) enrolled patients in the study. In the Phase 1a trial, BXQ-350 was well tolerated at all five dose levels with no dose limiting toxicities observed and with no serious adverse events attributed to the therapy. The highest dose is being utilized in the Phase 1b trial continuing at all four sites."
https://www.bexionpharma.com/press-releases/bexion-pharmaceuticals-inc-announces-initiation-of-phase-1b-clinical-trial-of-bxq-350-in-patients-with-advanced-solid-tumors/
Announcing a Phase I Pediatric Trial:
https://www.bexionpharma.com/press-releases/bexion-pharmaceuticals-inc-announces-grant-from-cancerfree-kids/
Getting into the trials:
https://clinicaltrials.gov/ct2/show/NCT02859857?term=BXQ&rank=1
————————-
Patient experiences:
Excellent human interest story (3 versions) on a single patient's use with the drug. The pressfrom site is the easiest to access while USAToday has a very unstable website and the Cincinnati somewhat unstable; note that both those versions differ from the original new source regarding the color of the drug (which seems like a weird difference).
Best site to access news story:
The first human trials of this experimental, cancer-killing drug could change everything
https://us.pressfrom.com/news/us/-175196-the-first-human-trials-of-this-experimental-cancer-killing-drug-could-change-everything/
Original source of story:
Patient No. 1 and the cancer trial here that just might change everything
https://www.cincinnati.com/story/news/2018/08/08/possible-answer-cancer-made-cincinnati/879696002/
Unstable website, but USAToday distributed story nationwide:
The first human trials of this experimental, cancer-killing drug could change everything
https://www.usatoday.com/story/news/nation-now/2018/08/09/researchers-test-experimental-drug-could-answer-cancer/948394002/
NoName is taking the same drug:
https://mondaymorning.com/2017/11/02/john-mccain-in-phase-1-trial-of-bexions-solid-cancer-tumor-candidate-bexion-who/
————————-
Technical info:
https://www.bexionpharma.com/press-releases/bexion-pharmaceuticals-inc-announces-initiation-of-phase-1b-clinical-trial-of-bxq-350-in-patients-with-advanced-solid-tumors/
https://www.nkytribune.com/2018/06/bexion-pharmaceuticals-inc-announces-data-from-ongoing-phase-i-bxq-350-clinical-trial/
How it works (very technical):
https://blogs.shu.edu/cancer/2015/02/25/bxq-350-pre-clinical-cancer-drug-with-novel-mechanism-of-action/
Journal abstract:
https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.2517
————————-
Has received Orphan Drug status:
"Orphan Drug status, which can be applied to experimental medicines for underserved patient populations or rare disorders affecting less than 200,000 people, entitles the company to a seven-year period of marketing exclusivity in the US following approval. … It also also enables the company to benefit from important financial, regulatory and commercial considerations, including tax credits for certain research expenses and a waiver from the FDA's application user fee …"
https://www.pharmatimes.com/news/us_orphan_status_for_bexions_brain_tumour_drug_971058#ixzz3S3zXdHlO
https://medcheminternational.blogspot.com/2015/02/us-orphan-status-for-bexions-brain.html